Latest Insider Transactions at Silverback Therapeutics, Inc. (SBTX)
This section provides a real-time view of insider transactions for Silverback Therapeutics, Inc. (SBTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Silverback Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Silverback Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$1,100,000
$11.67 P/Share
|
|
Dec 17
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$1,100,000
$11.67 P/Share
|
|
Dec 13
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
27,272
-16.66%
|
$327,264
$12.06 P/Share
|
|
Dec 13
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,272
+14.28%
|
$27,272
$1.44 P/Share
|
|
Dec 12
2024
|
Brian Dorsey Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-80.58%
|
$300,000
$12.3 P/Share
|
|
Dec 12
2024
|
Brian Dorsey Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+44.62%
|
$0
$0.64 P/Share
|
|
Dec 12
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
117,333
-46.25%
|
$1,407,996
$12.27 P/Share
|
|
Dec 12
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117,333
+31.62%
|
$0
$0.84 P/Share
|
|
Dec 11
2024
|
Brian Dorsey Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,000
-71.35%
|
$180,000
$12.43 P/Share
|
|
Dec 11
2024
|
Brian Dorsey Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+41.64%
|
$0
$0.64 P/Share
|
|
Dec 10
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-26.83%
|
$650,000
$13.15 P/Share
|
|
Dec 10
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.15%
|
$0
$0.84 P/Share
|
|
Dec 10
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-4.01%
|
$1,300,000
$13.17 P/Share
|
|
Dec 10
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-4.01%
|
$1,300,000
$13.17 P/Share
|
|
Dec 06
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Indirect |
11,876
+0.27%
|
$95,008
$8.42 P/Share
|
|
Dec 06
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,665
+0.37%
|
$102,660
$4.93 P/Share
|
|
Dec 06
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
25,665
+0.37%
|
$102,660
$4.93 P/Share
|
|
Dec 06
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,876
+0.27%
|
$95,008
$8.42 P/Share
|
|
Dec 06
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-26.83%
|
$700,000
$14.23 P/Share
|
|
Dec 06
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.15%
|
$0
$0.84 P/Share
|
|
Dec 05
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
49,640
-26.69%
|
$694,960
$14.13 P/Share
|
|
Dec 05
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,640
+21.06%
|
$0
$0.84 P/Share
|
|
Dec 04
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.81%
|
$585,000
$13.95 P/Share
|
|
Dec 04
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.88%
|
$0
$0.84 P/Share
|
|
Dec 04
2024
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,283
-52.46%
|
$87,962
$14.0 P/Share
|
|
Dec 04
2024
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,283
+34.41%
|
$6,283
$1.5 P/Share
|
|
Dec 04
2024
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
14,772
-6.56%
|
$192,036
$13.75 P/Share
|
|
Dec 04
2024
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
14,772
+6.16%
|
$44,316
$3.15 P/Share
|
|
Dec 03
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.81%
|
$585,000
$13.19 P/Share
|
|
Dec 03
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+10.49%
|
$0
$0.84 P/Share
|
|
Dec 03
2024
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
87,984
-29.49%
|
$1,143,792
$13.26 P/Share
|
|
Dec 03
2024
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
87,984
+13.54%
|
$175,968
$2.21 P/Share
|
|
Dec 02
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.81%
|
$585,000
$13.67 P/Share
|
|
Dec 02
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+19.88%
|
$0
$0.84 P/Share
|
|
Dec 02
2024
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,717
-39.5%
|
$52,038
$14.11 P/Share
|
|
Dec 02
2024
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,717
+28.32%
|
$3,717
$1.5 P/Share
|
|
Dec 02
2024
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
97,244
-15.87%
|
$1,264,172
$13.95 P/Share
|
|
Dec 02
2024
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
97,244
+14.18%
|
$97,244
$1.27 P/Share
|
|
Nov 27
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
25,000
-15.49%
|
$350,000
$14.39 P/Share
|
|
Nov 26
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
42,186
-20.72%
|
$590,604
$14.05 P/Share
|
|
Nov 25
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
32,814
-13.88%
|
$459,396
$14.0 P/Share
|
|
Nov 19
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-3.79%
|
$1,300,000
$13.95 P/Share
|
|
Nov 19
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-3.79%
|
$1,300,000
$13.95 P/Share
|
|
Nov 12
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-1.9%
|
$1,700,000
$17.2 P/Share
|
|
Nov 12
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-1.9%
|
$1,700,000
$17.2 P/Share
|
|
Nov 12
2024
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,814
-0.17%
|
$591,838
$17.47 P/Share
|
|
Nov 11
2024
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
528,456
-2.4%
|
$8,983,752
$17.8 P/Share
|
|
Oct 16
2024
|
Kathleen D. Scott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-71.64%
|
$200,000
$16.0 P/Share
|
|
Oct 16
2024
|
Kathleen D. Scott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+41.74%
|
$12,500
$1.5 P/Share
|
|
Oct 15
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-2.39%
|
$1,400,000
$15.0 P/Share
|